Change of synovial biomarkers and clinical outcomes in patients with Knee OA after platelet-rich plasma treatment. knee osteoarthritis, knee OA
Conditions
Interventions
Patients who undergo 2-cycle treatment of PRP at 6-week intervals.
,Patients who undergo 4-cycle treatment of PRP at 6-week intervals.
Treatment,Treatment
2-PRP injection patients.,4-PRP injection patients.
Sponsors
Chulalongkorn University
Eligibility
Sex/Gender
All
Age
45 Years to 85 Years
Inclusion criteria
Inclusion criteria: Selection criteria included knee OA according to the American College of Rheumatology (ACR), 45-85 years of age, grade 1 to 4 of radiographic knee OA according to the Kellgren-Lawrence system, body mass index (BMI) < 30, > 90-degree arc of motion, < 10-degree anatomical knee deformity in the coronal plane, and no skin lesion around the affected knee.
Exclusion criteria
Exclusion criteria: Exclusion criteria included inflammatory arthritis, previous knee surgery, knee pain with an antalgic gait, and thrombocytopenia. In addition, all recruited patients had a 2-week washing-out period for any pain killers or no non-steroidal anti-inflammatory drugs (NSAIDs), as well as joint supplements
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| synovial fluid biomarkers (inflammatory cytokines, anti-inflammatory cytokines, and growth factors) at a 6-week interval before each PRP injection of 2-cycle or 4-cycle PRP protocol until 18 weeks Level of all biomarkers using a commercial proteome cytokine array kit and reported in pg/mL | — |
Secondary
| Measure | Time frame |
|---|---|
| VAS, WOMAC, SF-12, Time up and go, 5-time sit to stand, and 3-minute walk test At 6 weeks, 12 weeks, 18 weeks, 6 months and 1 year VAS, WOMAC and SF-12 are evaluated using patient's report on the questionnaires. Time up and go, 5-time sit to stand and 3-minute walk tests are evaluated by clinical evaluators | — |
Countries
Thailand
Contacts
Public ContactWarayapa Mingsiritham
Chulalongkorn University
Outcome results
None listed